Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
DUVOID vs OCUSERT PILO-40
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Selective alpha-1A adrenergic receptor antagonist; relaxes smooth muscle in the bladder neck and prostate, reducing outflow resistance.
Direct-acting muscarinic agonist; mimics acetylcholine at muscarinic receptors in the eye, causing ciliary muscle contraction and pupillary sphincter contraction, leading to miosis and increased aqueous humor outflow.
Benign prostatic hyperplasia (BPH) - treatment of symptoms,Off-label: None established
Open-angle glaucoma,Ocular hypertension,Angle-closure glaucoma (emergency treatment),Induction of miosis during ophthalmic surgery,Off-label: Diagnostic miosis
100 mg orally three times daily.
One OCUSERT Pilo-40 (2.5 mcg/hr pilocarpine) inserted into the conjunctival cul-de-sac every 7 days.
Terminal elimination half-life is 12–15 hours in patients with normal renal function; prolonged to 24 hours or more in moderate-to-severe renal impairment.
Terminal elimination half-life is approximately 1-2 hours; clinical effect duration is extended due to the sustained-release delivery system.
Extensively metabolized in the liver primarily by CYP2D6 and CYP3A4, with possible minor contributions from other CYPs.
Primarily metabolized by plasma esterases via hydrolysis, with minor hepatic metabolism (CYP450 not significantly involved).
Renal elimination accounts for approximately 90% of a dose as unchanged drug; biliary/fecal excretion is minor (<10%).
Primarily renal (80-90% as unchanged drug and inactive metabolites); biliary/fecal excretion accounts for <5%.
Approximately 50–70% bound to plasma proteins, primarily albumin.
Binding to plasma proteins is negligible (<10%); primarily bound to tissue proteins in the eye.
Vd approximately 0.6 L/kg, indicating distribution into total body water.
0.3-0.6 L/kg in systemic circulation; local ocular distribution is extensive but systemic Vd is low.
Oral: 75–85% (may be decreased with food); subcutaneous: nearly 100%.
Systemic bioavailability is minimal (<1%) due to local ocular administration and first-pass hydrolysis; virtually 100% of the released dose is available locally in the eye.
GFR 30-89 m L/min: no adjustment; GFR <30 m L/min: avoid use.
No specific adjustment required; pilocarpine is primarily metabolized in the eye and systemic absorption minimal. GFR not relevant.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose to 50 mg twice daily; Child-Pugh C: avoid use.
No specific adjustment required; pilocarpine undergoes minimal hepatic metabolism. Child-Pugh not applicable.
Not recommended for use in pediatric patients.
Not established; safety and efficacy in pediatric patients not determined. Use only if clearly needed.
Initial dose 50 mg twice daily; titrate cautiously due to increased anticholinergic sensitivity.
No specific dose adjustment; consider potential increased risk of systemic effects due to reduced tear production or conjunctival changes. Monitor for bradycardia, hypotension, or bronchospasm.
None.
No FDA black box warning.
Orthostatic hypotension (especially dose-related; syncope reported),Intraoperative floppy iris syndrome (IFIS) during cataract surgery,Priapism (rare),Dizziness, somnolence, and fatigue may occur,Use caution with hepatic impairment,Avoid use with strong CYP3A4 inhibitors or inducers
Risk of retinal detachment, especially in patients with pre-existing retinal disease or high myopia,May cause transient or permanent miosis leading to reduced vision in low light,Ciliary spasm, headache, and brow ache,Potential for systemic absorption causing bradycardia, hypotension, and bronchospasm,Caution in patients with asthma, bradycardia, or hypotension
Hypersensitivity to DUVOID or any component,Moderate to severe hepatic impairment (Child-Pugh class B or C),Use with potent CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, ritonavir)
Hypersensitivity to pilocarpine or any component,Patients with acute inflammatory disease of the eye (e.g., iritis, uveitis),Uncontrolled asthma or severe bradycardia (systemic effects)
Take on an empty stomach; food may decrease absorption. Avoid alcohol as it may increase cholinergic side effects.
No significant food interactions known. Maintain adequate fluid intake. Avoid alcohol, which may increase risk of side effects like dizziness or blurred vision.
DUVOID (bethanechol) is classified as FDA Pregnancy Category C. No adequate studies in pregnant women. Animal reproduction studies have not been conducted. Fetal risk cannot be ruled out. Use only if potential benefit justifies potential risk to fetus. No known specific trimester risks.
Pilocarpine is a pregnancy category C drug. Animal studies have shown embryotoxic effects. In the first trimester, there is a potential risk of malformations. In the second and third trimesters, use may cause fetal bradycardia and hypotension. The benefit must justify the potential risk.
It is not known whether bethanechol is excreted in human milk. Caution should be exercised when administered to a nursing woman. M/P ratio is unknown.
Pilocarpine is excreted into breast milk. The M/P ratio is not established. Due to potential for systemic absorption in the infant, use while breastfeeding is not recommended. Monitor infant for cholinergic effects.
No formal pharmacokinetic studies in pregnancy. Due to increased plasma volume and renal clearance, dose adjustments may be necessary but specific recommendations are lacking. Use lowest effective dose and monitor clinical response.
Pregnancy may alter the pharmacokinetics of pilocarpine due to increased plasma volume and enhanced metabolic clearance. However, specific dose adjustment guidelines are not established. Titrate to the lowest effective dose to control intraocular pressure and monitor for systemic effects.
DUVOID (bethanechol) is a cholinergic agonist used for urinary retention. Monitor for cholinergic crisis (excessive salivation, sweating, bradycardia). Administer on an empty stomach to reduce GI upset. Avoid in patients with asthma, hyperthyroidism, peptic ulcer disease, or epilepsy. Atropine is the antidote for overdose.
Ocusert Pilo-40 is a sustained-release ocular insert delivering pilocarpine 40 mcg/hr for 7 days. Instruct patient to insert into conjunctival cul-de-sac at bedtime to minimize initial blurring and brow ache. Monitor for signs of retinal detachment, especially in myopic patients. Contraindicated in acute iritis, shallow anterior chamber, and narrow-angle glaucoma (can worsen angle closure). Use with caution in patients with corneal abrasions or ulcers. Systemic absorption can cause bradycardia, hypotension, and increased GI motility.
Take this medication on an empty stomach, 1 hour before or 2 hours after meals.,Report any signs of excessive sweating, salivation, or bradycardia to your healthcare provider.,Avoid driving or operating machinery until you know how this drug affects you.,Do not stop taking this medication abruptly; consult your doctor for dose adjustments.,Keep a list of all medications you take and share with your healthcare provider.
Wash hands before handling the insert. Do not touch the eye with the insert.,Insert the oval-shaped Ocusert into the lower conjunctival sac at bedtime; it should not be felt after placement.,The insert works for 7 days; replace with a new one weekly. Remove at the end of the week and discard.,Do not wear contact lenses with Ocusert in place. Remove lenses before insertion and wait 15 minutes before reinserting after removal.,Expect temporary blurred vision and brow ache for the first few hours to days; these side effects often decrease with continued use.,If the insert falls out, rinse it with cool tap water and reinsert quickly. If lost or damaged, use a new one.,Report severe eye pain, vision changes, or redness immediately.,Avoid driving or operating machinery until you know how this medication affects your vision.,Keep out of reach of children; do not use after expiration date.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about DUVOID vs OCUSERT PILO-40, answered by our medical review team.
DUVOID is a Cholinergic Agonist that works by Selective alpha-1A adrenergic receptor antagonist; relaxes smooth muscle in the bladder neck and prostate, reducing outflow resistance.. OCUSERT PILO-40 is a Ophthalmic Cholinergic Agonist that works by Direct-acting muscarinic agonist; mimics acetylcholine at muscarinic receptors in the eye, causing ciliary muscle contraction and pupillary sphincter contraction, leading to miosis and increased aqueous humor outflow.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between DUVOID and OCUSERT PILO-40 depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of DUVOID is: 100 mg orally three times daily.. The standard adult dose of OCUSERT PILO-40 is: One OCUSERT Pilo-40 (2.5 mcg/hr pilocarpine) inserted into the conjunctival cul-de-sac every 7 days.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between DUVOID and OCUSERT PILO-40 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. DUVOID is classified as Category C. DUVOID (bethanechol) is classified as FDA Pregnancy Category C. No adequate studies in pregnant women. Animal reproduction studies have not been conducted. Fetal risk cannot be rul. OCUSERT PILO-40 is classified as Category C. Pilocarpine is a pregnancy category C drug. Animal studies have shown embryotoxic effects. In the first trimester, there is a potential risk of malformations. In the second and thi. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.